18

“If a PDP, for example, invents a certain method for developing those products and also making them attractive for the pharmaceutical industry to either produce or sell, we would certainly be susceptible to that. That should be possible, as long as it is a fair and ethical solution.”—Publ1

19

If we are only taking the project through a phase where, to a clinical trial, then there is much more work to do and also much more expensive work. So somehow you need to offer a potential partner something and often the IP and the ability to generate a small profit, in the first world is one way to do that.”—Phil3